Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares Core S&P 500 ETF (IVV) vs Moderna, Inc. (MRNA) Price & Performance

iShares Core S&P 500 ETFTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

iShares Core S&P 500 ETF vs Moderna, Inc. — how do they compare? iShares Core S&P 500 ETF trades at $776.18, while Moderna, Inc. trades at $63.3 (market cap $24.18B). The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Moderna, Inc. nearer its low. Which is the better fit depends on your goals.

IVVMRNA
Sector
Broad Market / FactorHealth
52-Week High
$776.81$81.80
52-Week Low
$634.93$22.36
Market Cap
$24.18B
Enterprise Value
$20.33B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares Core S&P 500 ETF

IVV, tracking the S&P 500, trades at $776.38, down slightly by 0.04% amid broader market caution ahead of inflation data. The ETF shows a bullish technical signal with moving averages supporting upside, but oscillators are neutral and RSI levels indicate overbought conditions. Recent news highlights institutional interest, with First Bank & Trust increasing its stake, while JPMorgan raised its S&P 500 target to 8,000 for 2026, citing strong earnings and AI-driven growth (JPMorgan report, August 10, 2026).

Outlook remains positive due to robust corporate earnings and AI investments, but risks include high valuations and potential pullbacks from overbought levels. Investors should weigh the ETF's diversification benefits against market volatility and economic data sensitivity.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

Read more on IVV

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA